Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways

被引:108
作者
Romon, Rodrigue [1 ,2 ,4 ]
Adriaenssens, Eric [2 ,3 ,4 ]
Lagadec, Chann [1 ,2 ,4 ]
Germain, Emmanuelle [1 ,2 ,4 ]
Hondermarck, Hubert [1 ,2 ,4 ]
Le Bourhis, Xuefen [1 ,2 ,4 ]
机构
[1] INSERM, U908, F-59650 Villeneuve Dascq, France
[2] USTL, F-59650 Villeneuve Dascq, France
[3] Inst Pasteur, UMR 8161, CNRS, F-59800 Lille, France
[4] Univ Lille Nord France, F-59000 Lille, France
关键词
ENDOTHELIAL-CELL MIGRATION; NITRIC-OXIDE SYNTHASE; PROGNOSTIC VALUE; FACTOR EXPRESSION; NEUROTROPHIN RECEPTORS; COLORECTAL-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; BLOOD-VESSELS; TUMOR-GROWTH;
D O I
10.1186/1476-4598-9-157
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Although several anti-angiogenic therapies have been approved in the treatment of cancer, the survival benefits of such therapies are relatively modest. Discovering new molecules and/or better understating signaling pathways of angiogenesis is therefore essential for therapeutic improvements. The objective of the present study was to determine the involvement of nerve growth factor (NGF) in breast cancer angiogenesis and the underlying molecular mechanisms. Results: We showed that both recombinant NGF and NGF produced by breast cancer cells stimulated angiogenesis in Matrigel plugs in immunodeficient mice. NGF strongly increased invasion, cord formation and the monolayer permeability of endothelial cells. Moreover, NGF-stimulated invasion was under the control of its tyrosine kinase receptor (TrkA) and downstream signaling pathways such as PI3K and ERK, leading to the activation of matrix metalloprotease 2 and nitric oxide synthase. Interestingly, NGF increased the secretion of VEGF in both endothelial and breast cancer cells. Inhibition of VEGF, with a neutralizing antibody, reduced about half of NGF-induced endothelial cell invasion and angiogenesis in vivo. Conclusions: Our findings provided direct evidence that NGF could be an important stimulator for breast cancer angiogenesis. Thus, NGF, as well as the activated signaling pathways, should be regarded as potential new targets for anti-angiogenic therapy against breast cancer.
引用
收藏
页数:13
相关论文
共 49 条
[1]   Nerve growth factor is a potential therapeutic target in breast cancer [J].
Adriaenssens, Eric ;
Vanhecke, Elsa ;
Saule, Pasquine ;
Mougel, Alexandra ;
Page, Adeline ;
Romon, Rodrigue ;
Nurcombe, Victor ;
Le Bourhis, Xuefen ;
Hondermarck, Hubert .
CANCER RESEARCH, 2008, 68 (02) :346-351
[2]   Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors [J].
Calzà, L ;
Giardino, L ;
Giuliani, A ;
Aloe, L ;
Levi-Montalcini, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :4160-4165
[3]   Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer [J].
Campos, Ximena ;
Munoz, Yenny ;
Selman, Alberto ;
Yazigi, Roberto ;
Moyano, Leonor ;
Weinstein-Oppenheimer, Caroline ;
Lara, Hernan E. ;
Romero, Carmen .
GYNECOLOGIC ONCOLOGY, 2007, 104 (01) :168-175
[4]   Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo [J].
Cantarella, G ;
Lempereur, L ;
Presta, M ;
Ribatti, D ;
Lombardo, G ;
Lazarovici, P ;
Zappalà, G ;
Pafumi, C ;
Bernardini, R .
FASEB JOURNAL, 2002, 16 (08) :1307-+
[5]   Cardiovascular Actions of Neurotrophins [J].
Caporali, Andrea ;
Emanueli, Costanza .
PHYSIOLOGICAL REVIEWS, 2009, 89 (01) :279-308
[6]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[7]   Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon [J].
Cheung, N ;
Wong, MP ;
Yuen, ST ;
Leung, SY ;
Chung, LP .
HUMAN PATHOLOGY, 1998, 29 (09) :910-914
[8]   Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer [J].
Cianchi, F ;
Cortesini, C ;
Fantappiè, O ;
Messerini, L ;
Sardi, I ;
Lasagna, N ;
Perna, F ;
Fabbroni, V ;
Di Felice, A ;
Perigli, G ;
Mazzanti, R ;
Masini, E .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2694-2704
[9]  
Davidson B, 2003, CLIN CANCER RES, V9, P2248
[10]  
Descamps S, 2001, CANCER RES, V61, P4337